We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

90 hedge funds and large institutions have $343M invested in CytomX Therapeutics in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 14

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

7.76% more ownership

Funds ownership: 52.39% → 60.15% (+7.8%)

5% more funds holding

Funds holding: 86 → 90 (+4)

3% more capital invested

Capital invested by funds: $332M → $343M (+$11.1M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
90
Holders Change
+4
Holders Change %
+4.65%
% of All Funds
2.24%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
19
Increased
42
Reduced
14
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.1M
2
NI
Numeric Investors
Massachusetts
+$9.46M
3
BI
BVF Inc
California
+$3.35M
4
Renaissance Technologies
Renaissance Technologies
New York
+$2.65M
5
State Street
State Street
Massachusetts
+$2.49M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$2.81M
2
PA
Perceptive Advisors
New York
-$2.11M
3
MBT
Montecito Bank & Trust
California
-$1.78M
4
PAG
Private Advisor Group
New Jersey
-$1.46M
5
PI
Putnam Investments
Massachusetts
-$1.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$2.63M +$1.66M +109,791 +184%
EAM
27
Eventide Asset Management
Massachusetts
$2.33M – – –
Goldman Sachs
28
Goldman Sachs
New York
$1.98M +$1.76M +116,794 +1,064%
PAM
29
Panagora Asset Management
Massachusetts
$1.95M +$1.9M +125,834 +224,704%
Invesco
30
Invesco
Georgia
$1.89M +$1.37M +90,758 +293%
Charles Schwab
31
Charles Schwab
California
$1.82M +$265K +17,551 +18%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.79M +$442K +29,319 +34%
PAG
33
Private Advisor Group
New Jersey
$1.64M -$1.46M -97,177 -49%
Deutsche Bank
34
Deutsche Bank
Germany
$1.63M +$1.17M +77,315 +276%
Bank of America
35
Bank of America
North Carolina
$1.63M +$401K +26,588 +34%
Millennium Management
36
Millennium Management
New York
$1.59M -$983K -65,193 -39%
Nordea Investment Management
37
Nordea Investment Management
Sweden
$1.45M +$1.41M +93,613 New
VIA
38
Vident Investment Advisory
Georgia
$1.29M +$113K +7,468 +10%
FP
39
Foundry Partners
Minnesota
$1.19M +$1.15M +76,498 New
AllianceBernstein
40
AllianceBernstein
Tennessee
$1.14M +$589K +39,090 +113%
Morgan Stanley
41
Morgan Stanley
New York
$1.14M +$305K +20,266 +38%
TC
42
TFS Capital
Pennsylvania
$946K +$704K +46,703 +326%
IHM
43
Iguana Healthcare Management
New York
$930K -$226K -15,000 -20%
American Century Companies
44
American Century Companies
Missouri
$922K +$897K +59,516 New
TA
45
Teachers Advisors
New York
$809K +$260K +17,250 +49%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$797K +$169K +11,200 +28%
SO
47
STRS Ohio
Ohio
$737K +$537K +35,600 +297%
Wells Fargo
48
Wells Fargo
California
$639K +$284K +18,809 +84%
HP
49
Harbourvest Partners
Massachusetts
$608K +$214K +14,199 +57%
ROTUOC
50
Regents of the University of California
California
$566K -$514K -34,085 -48%
1
2
3 4 5

CTMX Hedge Fund Activity: Q2 2017 in Review

90 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2017, worth a combined $343M — up 3.4% from $332M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new CTMX positions and 15 closed out — a net gain of 4 holders — while 42 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $12.1M. The largest seller was Deerfield Management, cutting an estimated $2.81M.

  • 90 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2017, up from 86 in Q1 2017.
  • Funds reported $343M of CytomX Therapeutics stock for Q2 2017, up 3.4% quarter-over-quarter.
  • 19 funds opened new CytomX Therapeutics positions in Q2 2017 and 15 closed out, a net change of +4 holders.
  • The largest CytomX Therapeutics buyer in Q2 2017 was BlackRock, an estimated $12.1M added.
  • The largest CytomX Therapeutics seller in Q2 2017 was Deerfield Management, an estimated $2.81M sold.

Based on aggregated 13F filings for Q2 2017.